Logo do repositório
 
Publicação

Psychedelic treatments for mental health conditions pose challenges for informed consent

2023-09Outro Acesso aberto
Ver registo simples
dc.contributor.authorSeybert, Carolina
dc.contributor.authorCotovio, Gonçalo
dc.contributor.authorMadeira, Luís
dc.contributor.authorRicou, Miguel
dc.contributor.authorPires, Ana Matos
dc.contributor.authorOliveira-Maia, Albino J.
dc.contributor.authorOliveira-Maia, AJ
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionComprehensive Health Research Centre (CHRC) - pólo NMS
dc.contributor.pblNature Research
dc.date.accessioned2023-07-27T22:15:25Z
dc.date.available2023-07-27T22:15:25Z
dc.date.issued2023-09
dc.descriptionFunding Information: C.S. received payment from the European Monitoring Centre for Drugs and Drug Addiction. A.M.P. received payment or honoraria from Janssen and Lundbeck and participated in advisory boards for Janssen and Angelini. A.J.O.-M. was the national coordinator for Portugal of trials for treatment-resistant depression of psilocybin, sponsored by Compass Pathways, Ltd (EudraCT number 2017-003288-36), and of esketamine, sponsored by Janssen-Cilag, Ltd (EudraCT NUMBER: 2019-002992-33); received payment or honoraria from MSD, Neurolite AG, Janssen and the European Monitoring Centre for Drugs and Drug Addiction; participated in advisory boards for Janssen and Angelini; and is the recipient of a grant from Schuhfried GmBH. The remaining authors declare no competing interests. Funding Information: We thank C. E. Fisher and J. Taborda da Gama for comments on an initial version of this manuscript. This work was supported by grant PTDC/MED-NEU/31331/2017 from the Fundação para a Ciência e Tecnologia to C.S., G.C. and A.J.O.-M. A.J.O.-M. received other grants from the Fundação para Ciência e Tecnologia (PTDC/SAU-NUT/3507/2021; PTDC/MED-NEU/1552/2021) and the Fundação para Ciência e Tecnologia and FEDER (PTDC/MED-NEU/30845/2017_LISBOA-01-0145-FEDER-030845; PTDC/MEC-PSQ/30302/2017_LISBOA-01-0145-FEDER-30302), a Starting Grant from the European Research Council (grant agreement no. 950357) and grants from the European Union’s Horizon 2020 research and innovation program (H2020‑SC1‑2017‑CNECT‑2‑777167‑ΒΟUNCE; H2020‑SC1‑DTH‑2019‑875358‑FAITH) and the European Joint Programme in Rare Diseases (Joint Translational Call 2019) through the Fundação para Ciência e Tecnologia (EJPRD/0001/2020).
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1051413
dc.identifier.doi10.1038/s41591-023-02378-5
dc.identifier.issn1078-8956
dc.identifier.otherPURE: 66065610
dc.identifier.otherPURE UUID: 6b514c1c-dfd2-4ec7-9717-4f96373458f8
dc.identifier.otherScopus: 85163082734
dc.identifier.otherWOS: 001007644800001
dc.identifier.urihttp://hdl.handle.net/10362/155905
dc.identifier.urlhttps://www.scopus.com/pages/publications/85163082734
dc.language.isoeng
dc.peerreviewedyes
dc.subjectGeneral Biochemistry,Genetics and Molecular Biology
dc.subjectSDG 3 - Good Health and Well-being
dc.titlePsychedelic treatments for mental health conditions pose challenges for informed consenten
dc.typeother
degois.publication.issue9
degois.publication.titleNature Medicine
degois.publication.volume29
dspace.entity.typePublication
person.familyNameOliveira-Maia
person.givenNameAlbino Jorge
person.identifier.ciencia-idED15-6691-FEC7
person.identifier.orcid0000-0001-5071-3007
person.identifier.ridB-7976-2009
person.identifier.scopus-author-id14060820700
rcaap.rightsopenAccess
relation.isAuthorOfPublication402bb6ca-e5db-422a-9d43-a807d4076d38
relation.isAuthorOfPublication.latestForDiscovery402bb6ca-e5db-422a-9d43-a807d4076d38

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
s41591_023_02378_5.pdf
Tamanho:
1 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica